Literature DB >> 31719651

Characterization of a novel human BFL-1-specific monoclonal antibody.

Lahiru Gangoda1,2, Charis E Teh1,2, Michael A Dengler1,2, Sarah A Best1,2, Clare E Weeden1,2, Lin Tai1,2, Erinna F Lee3,4,5, Walter D Fairlie3,4,5, Kate D Sutherland1,2, Leonard C Harrison1,2, Daniel H Gray1,2, Andreas Strasser1,2, Marco J Herold6,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31719651      PMCID： PMC7206078          DOI： 10.1038/s41418-019-0454-y

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN： 1350-9047            Impact factor:   15.828


× No keyword cloud information.
  2 in total

1.  Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.

Authors:  Scott Boiko; Theresa Proia; Maryann San Martin; Gareth P Gregory; Michelle Min Wu; Neeraj Aryal; Maureen Hattersley; Wenlin Shao; Jamal C Saeh; Stephen E Fawell; Ricky W Johnstone; Lisa Drew; Justin Cidado
Journal:  Blood       Date:  2021-05-27       Impact factor: 22.113

2.  Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs.

Authors:  Lahiru Gangoda; Robyn L Schenk; Lin Tai; Pacman Szeto; Jen G Cheung; Andreas Strasser; Guillaume Lessene; Mark Shackleton; Marco J Herold
Journal:  Cell Death Dis       Date:  2022-04-04       Impact factor: 8.469
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.